Precision in the Brain, Insight for the Future: Prisys Biotech's MRI-Guided CNS Drug Delivery Platform
In the pursuit of breakthrough therapies for central nervous system (CNS) diseases, one of the greatest scientific challenges remains unchanged - how to deliver drugs precisely, efficiently, and safely into the brain.
The blood–brain barrier (BBB), while essential for neural protection, prevents more than 98% of drug candidates from reaching their intended targets. This limitation continues to hinder therapeutic development for neurodegenerative disorders, brain tumors, and genetic neurological diseases.
As a nonhuman primate (NHP) preclinical CRO, Prisys Biotech has built China's first industrial-grade MRI-guided intracerebral drug delivery platform, integrating real-time intraoperative imaging and stereotactic precision surgery. This platform provides translational bridge between preclinical CNS research and clinical neurosurgical applications.
Core Technology: Real-Time MRI-Guided Neurosurgical Precision
At the heart of the platform lies the ClearPoint® Navigation System, a intraoperative MRI (iMRI) guidance technology widely adopted in human neurosurgery. Prisys Biotech is the first in Asia to adapt this clinical-grade system for nonhuman primate research, achieving unprecedented precision and reproducibility in CNS drug delivery.
1. Real-Time Visualization - From Blind Injection to Direct Precision
Traditional intracerebral injections rely on preoperative imaging and anatomical estimation, which often lead to deviation due to brain shift during the procedure.
Prisys' iMRI-guided workflow enables researchers to operate directly inside the MRI scanner, monitoring the injection trajectory in real time. The cannula's position and infusion process are continuously visualized, achieving submillimeter accuracy and eliminating spatial uncertainty.
2. Convection-Enhanced Delivery (CED) - Achieving Uniform Distribution
Conventional injections face limitations such as reflux and uneven diffusion.
Prisys overcomes these challenges through Convection-Enhanced Delivery (CED) - a controlled, positive-pressure infusion technique that drives the therapeutic agent through the brain's extracellular matrix. This active diffusion mechanism ensures uniform drug distribution, minimizes backflow, and significantly expands the target coverage volume.
3. Minimally Invasive, Ethically Compliant, and Welfare-Oriented
Using ultra-thin, MRI-compatible SmartFlow cannulas, the platform minimizes tissue trauma, bleeding, and inflammatory responses.
Procedures are conducted under aseptic conditions, with rapid postoperative recovery, enabling longitudinal dosing studies and extended efficacy observation-all in compliance with AAALAC-accredited animal welfare standards.
Why Prisys Biotech? Key Advantages
| Dimension | Prisys Biotech's Advantage |
|---|---|
| Accuracy | Submillimeter navigation accuracy ensures precise targeting and consistent data. |
| Efficiency | CED technology maximizes intracerebral drug distribution while minimizing dose and risk. |
| Safety | Minimally invasive operation with real-time visualization enhances animal welfare and procedural reliability. |
| Translational Value | The same ClearPoint® navigation technology is used in human clinical neurosurgery, ensuring high data predictability for IND and FIH studies. |
| Versatility | Fully compatible with CNS modalities, including AAV gene therapy, cell therapy, ASO/siRNA delivery, viral vectors, and biologics. |
Applications: Enabling Next-Generation CNS Therapeutics
Prisys Biotech's iMRI-guided drug delivery platform empowers preclinical research across a wide range of CNS indications:
Neurodegenerative Diseases: Targeted AAV or ASO delivery for Parkinson's disease, Alzheimer's disease, and Huntington's disease.
Brain Tumors: Precise intracranial administration of oncolytic viruses, chemotherapeutics, or nanoparticles into glioma lesions.
Genetic Neurological Disorders: Preclinical assessment of gene replacement or silencing therapies.
Ischemic and Hemorrhagic Stroke: Local infusion of neuroprotective agents or trophic factors into defined cortical or subcortical regions.
From Bench to Brain - Bridging Translational Neuroscience
By integrating MRI-guided navigation, CED infusion control, and nonhuman primate neuroscience expertise, Prisys Biotech provides a clinically aligned CNS research platform that bridges preclinical drug development and clinical neurosurgical innovation.
Our scientific and surgical teams collaborate closely with global biopharmaceutical partners to validate delivery systems, optimize formulations, and de-risk translational programs-accelerating the journey of CNS therapies from concept to clinical trial.
Contact Prisys Biotech
📧 bd@prisysbiotech.com
🌐 www.prisysbiotech.com
